United States.

Biopharma wants to demonstrate added value to payers, employers, and self-paying patients with high deductibles. At the same time, prescribers have enormous choice in most classes and must see meaningful differentiation to prescribe. Finally, FDA is increasingly requiring risk management programs where enhanced support must be provided to patients, prescribers and pharmacists. In the US, Human Care Systems solutions add value to all key stakeholders via an easier patient and prescriber experience, better health outcomes, and fulfillment of risk management requirements.

Europe, Japan, South Korea, Australia, Singapore, Canada.

All industrialized National Payer markets are looking for solutions like therapy management to improve outcomes and cost efficiency. EMEA, MHLW and other regulatory bodies increasingly require risk management programs where enhanced support must be provided to patients, prescribers and pharmacists. In industrialized National Payer markets, Human Care Systems solutions help build the best possible health economics dossiers and fulfill risk management requirements.

Emerging Markets.

There is a need to engage and show greater value to the trinity of self-pay patients, powerful neighborhood pharmacists, and physicians. This is critical for brands as well as branded generics. In addition, regulatory bodies and physician groups have been clamping down on previously existing 'added value' practices (e.g., CFM 1939/2010 in Brasil). There is an opportunity to use voice / text technology to engage patients in better self-care and leverage powerful community pharmacist relationships, especially with a lack of patient-oriented nurses in many locations, and high mobile phone penetration even outside the most urban areas. In Emerging Markets, Human Care Systems solutions can provide a premier experience to patients, engage pharmacists, differentiate to physicians, and abide by regulatory and ethical guidelines.